170 related articles for article (PubMed ID: 38011391)
1. Medical history risk factors in primary progressive multiple sclerosis: A case-control study.
Maroufi H; Moghadasi AN; Rezaei-Aliabadi H; Sahraian MA; Eskandarieh S
Curr J Neurol; 2021 Apr; 20(2):86-94. PubMed ID: 38011391
[No Abstract] [Full Text] [Related]
2. Stressful life events and the risk of primary progressive multiple sclerosis: A population-based case-control study.
Alsharie AM; Rafiee F; Rezaeimanesh N; Moghadasi AN; Sahraian MA; Eskandarieh S
Mult Scler Relat Disord; 2021 Jun; 51():102937. PubMed ID: 33857898
[TBL] [Abstract][Full Text] [Related]
3. Waterpipe and cigarette smoking and drug and alcohol consumption, and the risk of primary progressive multiple sclerosis: A population-based case-control study.
Mortazavi SH; Moghadasi AN; Almasi-Hashiani A; Sahraian MA; Goudarzi H; Eskandarieh S
Curr J Neurol; 2023 Apr; 22(2):72-81. PubMed ID: 38011368
[No Abstract] [Full Text] [Related]
4. Dietary risk factors of primary progressive multiple sclerosis: A population-based case-control study.
Rezaeimanesh N; Moghadasi AN; Sahraian MA; Eskandarieh S
Mult Scler Relat Disord; 2021 Nov; 56():103233. PubMed ID: 34488182
[TBL] [Abstract][Full Text] [Related]
5. Comparing epidemiology and baseline characteristic of multiple sclerosis and neuromyelitis optica: A case-control study.
Eskandarieh S; Nedjat S; Abdollahpour I; Moghadasi AN; Azimi AR; Sahraian MA
Mult Scler Relat Disord; 2017 Feb; 12():39-43. PubMed ID: 28283104
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
8. Stressful life events, socioeconomic status, and the risk of neuromyelitis optica spectrum disorder: A population-based case-control study.
Rafiee F; Tarjoman T; Moghadasi AN; Sahraian MA; Azimi A; Rezaeimanesh N; Eskandarieh S
Mult Scler Relat Disord; 2020 Nov; 46():102544. PubMed ID: 33032056
[TBL] [Abstract][Full Text] [Related]
9. Real-world challenges in the diagnosis of primary progressive multiple sclerosis.
Blok KM; Smolders J; van Rosmalen J; Martins Jarnalo CO; Wokke B; de Beukelaar J
Eur J Neurol; 2023 Dec; 30(12):3799-3808. PubMed ID: 37578087
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
11. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
Jia X; Madireddy L; Caillier S; Santaniello A; Esposito F; Comi G; Stuve O; Zhou Y; Taylor B; Kilpatrick T; Martinelli-Boneschi F; Cree BAC; Oksenberg JR; Hauser SL; Baranzini SE
Ann Neurol; 2018 Jul; 84(1):51-63. PubMed ID: 29908077
[TBL] [Abstract][Full Text] [Related]
12. [Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists].
Vlasov YV; Churakov MV; Kurapov MA; Gromova TN; Popova EV; Boyko OV; Spirin NN; Sivertseva SA; Belskaya GN; Malkova NA; Habirov FA; Haybullin TI; Kotov SV; Greshnova IV; Ivashinenkova EI; Bakalova MA; Yampolskaya-Gosteva IA; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8. Vyp. 2):40-46. PubMed ID: 30160667
[TBL] [Abstract][Full Text] [Related]
13. A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis.
Kelly SB; Kinsella K; Duggan M; Tubridy N; McGuigan C; Hutchinson M
Mult Scler; 2013 Jul; 19(8):1095-100. PubMed ID: 23132903
[TBL] [Abstract][Full Text] [Related]
14. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
15. Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria.
de Seze J; Debouverie M; Waucquier N; Steinmetz G; Pittion S; Zephir H; Fleury M; Blanc F; Vermersch P
Mult Scler; 2007 Jun; 13(5):622-5. PubMed ID: 17548441
[TBL] [Abstract][Full Text] [Related]
16. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
17. Prodrome in relapsing-remitting and primary progressive multiple sclerosis.
Wijnands JMA; Zhu F; Kingwell E; Zhao Y; Evans C; Fisk JD; Marrie RA; Tremlett H
Eur J Neurol; 2019 Jul; 26(7):1032-1036. PubMed ID: 30714270
[TBL] [Abstract][Full Text] [Related]
18. The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.
Boles GS; Hillert J; Ramanujam R; Westerlind H; Olsson T; Kockum I; Manouchehrinia A
Mult Scler; 2023 Sep; 29(10):1209-1215. PubMed ID: 37435869
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
20. Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis.
Chow HH; Talbot J; Marstrand L; Lundell H; Roman Siebner H; Bach Søndergaard H; Sellebjerg F
Mult Scler Relat Disord; 2021 Nov; 56():103296. PubMed ID: 34678704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
